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Abstract
Healthcare Associated Infections (HAI) are a global concern, further threatened by the
increasing drug resistance of HAI-associated pathogens. On the other hand, persistent con-
tamination of hospital surfaces contributes to HAI transmission, and it is not efficiently con-
trolled by conventional cleaning, which does not prevent recontamination, has a high
environmental impact and can favour selection of drug-resistant microbial strains. In the
search for effective approaches, an eco-sustainable probiotic-based cleaning system (Pro-
biotic Cleaning Hygiene System, PCHS) was recently shown to stably abate surface patho-
gens, without selecting antibiotic-resistant species. The aim of this study was to determine
whether PCHS application could impact on HAI incidence. A multicentre, pre-post interven-
tional study was performed for 18 months in the Internal Medicine wards of six Italian public
hospitals (January 1st 2016—June 30th 2017). The intervention consisted of the substitution
of conventional sanitation with PCHS, maintaining unaltered any other procedure influenc-
ing HAI control. HAI incidence in the pre and post-intervention period was the main outcome
measure. Surface bioburden was also analyzed in parallel. Globally, 11,842 patients and
24,875 environmental samples were surveyed. PCHS was associated with a significant
decrease of HAI cumulative incidence from a global 4.8% (284 patients with HAI over 5,930
total patients) to 2.3% (128 patients with HAI over 5,531 total patients) (OR = 0.44, CI 95%
0.35–0.54) (P<0.0001). Concurrently, PCHS was associated with a stable decrease of
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surface pathogens, compared to conventional sanitation (mean decrease 83%, range 70–
96.3%), accompanied by a concurrent up to 2 Log drop of surface microbiota drug-resis-
tance genes (P<0.0001; Pc = 0.008). Our study provides findings which support the impact
of a sanitation procedure on HAI incidence, showing that the use of a probiotic-based envi-
ronmental intervention can be associated with a significant decrease of the risk to contract a
HAI during hospitalization. Once confirmed in larger experiences and other target popula-
tions, this eco-sustainable approach might be considered as a part of infection control and
prevention (IPC) strategies.
Trial registration—ISRCTN International Clinical Trials Registry, ISRCTN58986947.
Introduction
Healthcare-associated infections (HAIs) are a global concern impairing the clinical outcome
of up to 15% of all hospitalized patients in the world [1]. In Europe, about 3.2 million patients
acquire a HAI every year, and 37,000 die as a HAI direct consequence and also because of the
increasing multi-drug resistance (MDR) of HAI-associated pathogens [1, 2]. Studies con-
ducted in Italian hospitals show a 5–10% HAI incidence with a mortality rate up to 20–30%
[3–5].
On the other hand, it is known that hospital surfaces are persistently contaminated by
many microorganisms which can contribute to HAI transmission [6–11], as surfaces represent
the reservoir of several pathogens spread by hospital inpatients and personnel [6, 8, 10–15].
Control of surface contamination has been so far approached by conventional chemical-based
sanitation, which has limitations, as it cannot prevent recontamination phenomena [16–19],
has an high environmental impact, and can contribute to selection of disinfectant-resistant
and even antibiotic-resistant pathogens [20, 21], potentially contributing to a further increase
of HAI-associated MDR pathogens [22, 23].
Recently, the ‘health’ of hospital surfaces has been re-thought as the health of the human
body, considering that, rather than eradicating all pathogens, replacing them by beneficial
microbes might be more effective in preventing infections [24, 25]. Toward this principle, a
sanitation approach based on eco-sustainable detergents containing spores of Bacillus probiot-
ics (Probiotic Cleaning Hygiene System, PCHS) was recently studied, showing that it is safe
for hospitalized patients [26], it can stably decrease surface pathogens up to 90% more than
conventional disinfectants [27, 28], and it does not select for resistant strains, rather reducing
them [29], without increasing sanitation costs [27, 30].
Here we aimed to analyze the impact on HAI incidence by implementing an 18-month
multicentre interventional study (from January 1st 2016 to June 30th 2017) in six Italian hospi-
tals, to assess whether the unique use of an innovative eco-sustainable microbial-based clean-
ing procedure can influence HAI occurrence.
Methods
Study design and participants
A multicentre, prospective, pre-post interventional study simultaneously analyzing surface
contamination and HAI incidence was conducted in six public medium to large Italian hospi-
tals for 18 months (from January 1st 2016 to June 30th 2017). The trial protocol was approved
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by the Institutional Ethics Committees of each enrolled healthcare structure. The trial was reg-
istered in the ISRCTN Registry (ISRCTN58986947).
Eligibility criteria for enrolled hospitals included: i) approval of local ethical committee
before entering the study, ii) presence of internal medicine/geriatrics and neurology wards
(which were included in the study), iii) size larger than 100 in-patients beds, iv) presence of an
established HAI surveillance program and infection control team, v) acceptance not to intro-
duce any new intervention focused on Infection Control and Prevention (ICP), potentially
affecting HAI incidence, except those already existing in the enrolled hospital wards and those
necessary to manage possible outbreaks, throughout the whole study.
Enrolled hospitals represented different geographical Italian regions (North, Centre and
South), and were randomly allocated in one of two Intervention groups (I1, I2). One further
hospital, meeting all eligibility criteria, was included as an external contemporaneous control
(extC), as it did not receive intervention and was only monitored for HAI incidence and envi-
ronmental bioburden. I1-group included three hospitals entering the study on January 1
st 2016
(Feltre, Roma, Foggia); I2-group included two hospitals entering 5-months later, on May 1
st
2016 (Vigevano and Tolmezzo); the extC hospital was monitored starting from May 1
st 2016, as
for I2 group (Messina). Random allocation was performed by an independent investigator
using computer-generated random numbers.
The intervention consisted uniquely of the introduction of PCHS sanitation (a patented sys-
tem by Copma, Ferrara, Italy), replacing the conventional chemical-based (chlorine products)
one. Enrolled hospitals agreed not to introduce any other intervention potentially affecting
HAI incidence throughout the whole study, except those already existing at the enrolment
time. Cleaning staff did not change during the study and were adequately trained for the
appropriate PCHS application in all the hospitals receiving the intervention. More precisely,
no general cleaning topics were covered, as the training was limited to the correct modalities
to prepare and use the PCHS cleansers. No other differences were introduced, either in num-
ber and qualification of cleaning staff, nor in frequency of the procedures, resulting in no dif-
ferent perception by cleaning staff, healthcare personnel and patients about the change of the
cleaning system. Healthcare personnel, data extractors and patients were not aware about the
change of the cleaning system.
The study included two phases: a 6 month pre-intervention period (pre-PCHS), when hos-
pitals maintained the conventional chemical-based sanitizing procedures, and a 6 month post-
intervention period (PCHS), when PCHS was routinely applied, with a minimum 2 month
interval between the two phases, when PCHS was introduced.
All new patients admitted at the enrolled wards in the pre-PCHS and PCHS periods were
included in the study and surveyed for the development of HAIs, without distinction of age or
gender and keeping their identity completely anonymous, so that informed consent was not
needed. Surveillance of HAIs was already done in all enrolled hospitals, and not implemented
for the study, but during the study HAIs were monitored daily, in continuum, in order to
obtain their true incidence value. Patients already present at the beginning of pre-PCHS and
PCHS periods, and in the window period between pre-PCHS and PCHS phases, were
excluded. Observation of patients was stopped on the last day of pre-PCHS and PCHS periods.
HAI analyses
Each HAI occurring during the observation periods in the patients admitted to the enrolled
hospital wards in the two observed periods was identified according to the criteria defined by
the European Centre for Disease Prevention and Control (ECDC) [31]. All HAI types were
included in the study, namely: urinary tract infections (UTI), bloodstream infections (BSI)
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including those central-vascular catheter (CVC)-related, systemic-clinical sepsis, gastrointesti-
nal infections (GI), skin and soft tissue infections, pneumonia, lower respiratory tract infec-
tions (LRI), surgical site infections (SSI), reproductive tract infections, EENT (eye, ear, nose
and throat or mouth) infections, bone and joint infections, intra-abdominal infections, and
non-specified infections.
HAI etiological agents were identified by microbiology laboratories of each hospital, based
on routine diagnostic tests. No changes were applied to the conventional diagnostic process of
each hospital, except for Bacillus species for which routine searches were done in all clinical
samples.
Environmental sampling and analyses
Hospital surface microbiota was analyzed monthly by a central team (CIAS centre, University
of Ferrara). To this aim, three points/room (floor, bed footboard and sink) were sampled in
duplicate as previously described [27, 29], in 3–6 randomized rooms/hospital (respectively in
hospitals with less or more than 100 enrolled ward beds). Total bacteria, Staphylococcus spp.,
Enterobacteriaceae spp., Acinetobacter spp., Mycetes, Pseudomonas spp., and Clostridium diffi-
cile were quantified on specific Rodac contact plates (CFU/m2).
Quarterly (twice in the pre-PCHS and twice in the PCHS phases), the same points were also
analyzed by molecular assays, as previously described [29]. Briefly, total bacterial amount,
Bacillus count and microbiota resistome were respectively quantified by panB real time quanti-
tative PCR (panB-qPCR), spo0A-qPCR and a qPCR microarray for 84 resistance genes (Qiagen
Antibiotic Resistance Genes, BAID-1901ZRA, Hilden, Germany). Resistome was also analyzed
in four PCHS-Bacillus isolates from each sampling campaign of the PCHS-phase.
Data collection and management
Dedicated healthcare professionals (recruited and trained in a standard way) collected in con-
tinuum data from patients’ clinical records in a standardised spreadsheet, per each hospital.
Professionals collecting clinical data were only aware of an incidence study to be conducted
during all the study period (18 months), and were blinded to the intervention time and hospi-
tal’s groups.
A first electronic clinical record was filled out for each admitted patient, and contained gen-
eral data: gender, age, origin, admission date, admission diagnosis, presence of specific risk
factors, antibiotic therapy in the two weeks preceding admission, presence of colonization by
alert microorganisms, eventual presence of infection at admission and its etiological agent.
A second form, filled out in case of HAI onset, included information about HAI onset, loca-
tion, etiological agent, drug therapy and infection resolution/outcome. All data were anonymized
and submitted centrally via a secure, password-protected website. A central team was available
during the whole study period to solve informatics problems, standardizing and validating com-
pleteness of data and their consistency. Data analyzers were blinded to the intervention time and
hospital’s allocation. A quota corresponding to at least 10 recorded HAIs per hospital setting were
validated by a blinded second expert, to minimize the risk of infection miscoding.
Bioburden data, collected monthly by the central team (University of Ferrara), were also
uploaded in the same password-protected website.
Outcome measures
The primary outcome measure was the reduction of HAI incidence in the PCHS compared to
the pre-PCHS phase. Variations in infection rates were analyzed both as cumulative incidence
per 100 admitted patients, and as HAIs incidence rates per 1,000 patient days. Secondary
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outcome measures were qualitative and quantitative characterisation of hospital surface bio-
burden in the surveyed areas.
Statistical methods
The study power was estimated based on admissions and HAI incidence rates in Italian hospi-
tals [3–5]. The sample size was calculated considering an 80% power to detect an infection
incidence reduction of at least 25% starting from a hypothesized rate of 4%, assuming a two-
sided test with an alpha level of 0.05, and corresponded to 10,476 patients.
Statistical analyses were performed using chi-square test, Kolmogorov-Smirnov test for
evaluating normality, parametric (Student’s t test) and non-parametric (Mann-Whitney) tests,
chi-square test of association, and multivariable analysis (logistic regression), assuming as sta-
tistically significant a P value at least <0.05. Multivariable model was developed including all
the parameters which showed a statistically significant correlation with HAI occurrence by
univariate analysis. Bonferroni correction for multiple comparisons was applied for analysis of
microarray data (a Pc value<0.05 was considered significant). Analyses were performed using
the software IBM1 SPSS201 Statistics (IBM, Bologna, Italy).
Recruitment
All enrolled hospitals completed the study, guaranteeing a continuous monitoring for a
6-months period in the pre-intervention (pre-PCHS) phase and a 6-months period in the
intervention (PCHS) phase (Fig 1). Overall, the study surveyed 11,842 patients, 11,461 from
intervention I1-I2 hospitals and 381 from the external control hospital (Table 1). Globally
24,875 environmental samples were analyzed.
Results
Impact of sanitation on HAI incidence
Globally 11,842 patients were surveyed, all hospitalized in the Internal Medicine wards of the
enrolled hospitals, this aimed to analyze the incidence of HAIs in a more homogeneous
patients’ sample possible.
Table 1 summarizes the main characteristics of the studied population by a participating
hospital. HAI cumulative incidence (patients with HAI/enrolled patients) decreased signifi-
cantly in the PCHS period compared to the pre-PCHS phase of the I1-I2 hospitals, from 4.8%
(283/5,930) to 2.3% (128/5,531) (range 1.3–3.7%) (P<0.0001), regardless of the geographical
location and entering time in the study. HAI incidence rate per 1,000 patient-days decreased
from 5.4 (314/57,742) to 2.4 (141/58,201), with an incidence rate ratio of 0.45 (95% CI, 0.36–
0.54). The decrease was evident in each individual hospital, including the structure with a pre-
vious very low HAI incidence (Tolmezzo, from 2.1% to 1.7%). A slight not significant reduc-
tion was observed also in the external control hospital, where the total number of HAIs was 15
infections in 12 patients in the first 6-month period, and 16 infections in 16 patients in the sec-
ond one, with a respective cumulative incidence rate of 8.2% and 6.8% (OR = 0.82; 95% CI,
0.37–1.78; P = 0.6), and a relative incidence rate per 1,000 patient-days corresponding to 9.4
(15/1,600) and 7.0 (16/2,279) respectively (OR = 0.75; 95% CI, 0.37–1.54).
The analysis of HAI incidence bimonthly rates in the pre-PCHS and PCHS phases, showed
no tendency to decrease in the pre-PCHS period, prior to the intervention, whereas a stable
reduction was observed following the introduction of PCHS sanitation (Fig 2).
The main clinical features of the observed patients were very similar in the pre-PCHS and
PCHS periods of the study, as shown in Table 2. The univariate analysis results confirmed as
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risk factors for HAI occurrence those already reported in the literature, indicating for example
a positive correlation with the presence of urinary or central venous catheters and increasing
age, whereas a protective effect emerged for being a male and self-sufficiency (S1 Table).
Among all the observed HAIs, urinary tract infections (UTI) represented the most preva-
lent infection type (Table 3), followed by bloodstream infections (BSI), systemic clinical sepsis,
gastrointestinal infections (GI), skin and soft tissue infections, and respiratory infections. Fol-
lowing PCHS intervention, the cumulative incidence of the most frequent HAIs decreased:
UTI, from 3% (179/5,930) to 1.2% (70/5,531); bloodstream infections-BSI, from 0.9% (54/
5,930) to 0.6% (31/5,531); clinical sepsis, from 0.4% (22/5,930) to 0.1% (5/5,531); gastro-intes-
tinal infections from 0.3% (17/5,930) to 0.1% (6/5,531); and skin/soft tissue infections from
0.3% (16/5,930) to 0.1% (6/5,531). Instead, the relative burden of each HAI type did not change
significantly in the PCHS phase compared to the pre-PCHS one.
Similarly, the number of HAI-associated microorganisms (identified in HAI patients)
decreased significantly from 332 in the pre-PCHS phase to 137 in the PCHS phase (Table 4),
whereas the relative percentages of isolated microorganisms remained unaltered: E. coli, E. fae-
calis, S. aureus, P. mirabilis and P. aeruginosa were in fact the most frequently isolates in both
Fig 1. Study design graphic representation. Six Italian hospitals from different geographical regions were enrolled in
the study (North: Feltre, Tolmezzo, Vigevano; Centre: Rome; South: Foggia, Messina). Five hospitals were randomly
allocated in two Intervention groups (I1, I2) and one further hospital represented an external control (extC): I1-group
included Roma, Foggia and Feltre hospitals, entering the study on January 1st 2016; I2-group included Vigevano and
Tolmezzo hospitals, entering 5-months later, on May 1st 2016; extC hospital was represented by Messina hospital,
receiving no intervention and monitored from May 1st 2016. The phases of the study are indicated by colours: orange,
6-months pre-intervention period (pre-PCHS); light green, stabilization period, when PCHS was introduced; green,
6-months post-intervention period (PCHS), when PCHS was routinely applied. Sampling campaigns for
microbiological analyses are indicated by circles: conventional microbiological analyses were performed monthly
(black circles), and molecular analyses were performed quarterly (red circles) in all enrolled hospitals.
https://doi.org/10.1371/journal.pone.0199616.g001
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phases. Importantly, no infections sustained by PCHS-derived Bacilli were detected in any of
the hospitalized patients in the enrolled structures, further supporting the absence of infectious
risks associated with PCHS-Bacilli use indicated by previous studies.
The relative role of PCHS in the reduction of HAI onset was explored by a multivariable
model including all the parameters emerged as variables positively associated with HAI occur-
rence by univariate analysis. The results (summarized in Table 5), while confirming as
Table 1. Population characteristics of study participants in pre-PCHS and PCHS phases, stratified by enrolled hospitals.
Patients
No.
Age
(mean±SD)
Length of stay
(mean±SD)
Patients with at least one HAI
No. (%)
Group Healthcare Structure Total Pre-PCHS PCHS Pre-PCHS PCHS Pre-PCHS PCHS Pre-PCHS PCHS Statistical significance
I1 Feltre 2,812 1,599 1,213 73.1±16.4 74.9±15.4 8.7±5.7 10.0±6.1 77 (4.8%) 30 (2.5%) P = 0.0013
OR, 0.50
95% CI, 0.33–0.77
Foggia 1,951 966 985 72.4±15.9 74.7±14.8 9.9±5.4 12.0±7.1 106 (11.0%) 36 (3.7%) P<0.0001
OR, 0.31
95% CI, 0.21–0.45
Roma 3,116 1,611 1,505 68.0±17.8 68.1±17.2 10.4±8.9 11.0±7.3 50 (3.1%) 20 (1.3%) P = 0.0008
OR, 0.42
95% CI, 0.25–0.71
I2 Tolmezzo 2,453 1,186 1,267 74.3±14.3 75.9±13.3 10.6±9.8 9.8±6.3 25 (2.1%) 21 (1.7%) P = 0.4111
OR, 0.78
95% CI, 0.44–1.41
Vigevano 1,129 568 561 72.7±15.5 72.6±16.1 8.9±5.4 9.6±6.2 26 (4.6%) 21 (3.7%) P = 0.4829
OR, 0.81
95% CI, 0.45–1.46
Tot. (I1+I2) 11,461 5,930 5,531 71.8±16.4 73.0±15.8 9.7±7.6 10.5±6.7 284 (4.8%) 128 (2.3%) P<0.0001
OR, 0.47
95% CI, 0.38–0.58
extC Messina 381 146 235 71.3±14.9 72.3±15.7 11.6±8.9 9.7±5.7 12 (8.2%) 16 (6.8%) P = 0.6080
OR, 0.82
95% CI, 0.37–1.78
I1, Intervention group 1; I2, Intervention group 2; extC, external control hospital.
https://doi.org/10.1371/journal.pone.0199616.t001
Fig 2. HAI incidence rates in the I1-I2 intervention hospitals. Results are expressed as bimonthly value of incidence
rate per 1,000 patient-days, respectively in the pre-PCHS (red) and PCHS periods (blue). 95% CI intervals are also
reported.
https://doi.org/10.1371/journal.pone.0199616.g002
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Table 2. Patient characteristics of the I1-I2 hospitals in the pre-PCHS and PCHS periods (11,461 patients).
Patients characteristics Pre-PCHS PCHS
Total patients
No. (%)
Total patients
No. (%)
Total 5,930 5,531
Gender: male 2,977 (50.2%) 2,928 (52.9%)
Age <65 1,518 (25.6%) 1,265 (22.9%)
Age 65–74 1,261 (21.3%) 1,177 (21.3%)
Age 75–84 1,821 (30.7%) 1,753 (31.7%)
Age85 1,330 (22.4%) 1,336 (24.2%)
Incontinence 1,448 (24.4%) 1,369 (24.8%)
Disorientation 804 (13.6%) 747 (13.5%)
Self-sufficiency 3,671 (61.9%) 3,632 (65.7%)
Pressure sores 393 (6.6%) 237 (4.3%)
Surgery 30 day before 122 (2.1%) 80 (1.4%)
Ventilation 215 (3.6%) 161 (2.9%)
Parenteral nutrition 200 (3.4%) 141 (2.5%)
ATB 2 week before 566 (9.5%) 294 (5.3%)
MDRO at admission 131 (2.2%) 83 (1.5%)
Infection at admission 1,216 (20.5%) 1,089 (19.7%)
Urinary catheter (any type) 1,368 (23.1%) 1,166 (21.1%)
CVC 264 (4.5%) 260 (4.7%)
Self-sufficiency, ability to provide for themselves autonomously, measured by SSM (Self Sufficiency Matrix) scale;
ATB, antibiotics; MDRO, multi drug resistant organism; CVC, central vascular catheter.
https://doi.org/10.1371/journal.pone.0199616.t002
Table 3. HAIs in pre-PCHS and PCHS phases, stratified by type.
Pre-PCHS
(I1 + I2)
No. (%)
PCHS
(I1 + I2)
No. (%)
extC
1st 6-months period
No. (%)
extC
2nd 6-months period
No. (%)
No. of HAIs 314 (100%) 141˚ (100%) 15# (100%) 16§ (100%)
Type Urinary tract infections-UTI 179 (57.0%) 70 (49.6%) 8 (53.3%) 6 (37.5%)
Bloodstream infections-BSI [CVC related] 54 [10] (17.2%) 31 [7] (22.0%) - 3 (18.8%)
Clinical sepsis 22 (7.0%) 5 (3.5%) 1 (6.7%) -
Gastrointestinal-GI 17 (5.4%) 6 (4.3%) 2 (13.3%) -
Skin and soft tissue 15 (4.8%) 6 (4.3%) 3 (20.0%) 1 (6.2%)
Pneumonia 12 (3.8%) 8 (5.7%) - 2 (12.5%)
Lower respiratory tract 10 (3.2%) 6 (4.3%) 3 (18.8%)
Reproductive tract 1 (0.3%) - - -
Eye, ear, nose and throat or mouth EENT 1 (0.3%) 2 (1.4%) - -
Bone and joint - 1 (0.7%) - -
Intra-abdominal - 1 (0.7%) - -
Surgical Site Infection - - - 1 (6.2%)
Not specified 3 (1.0%) 5 (3.5%) 1 (6.7%) -
 256 patients with 1 HAI, 26 with 2 HAIs, and 2 with 3 HAIs
˚ 115 patients with 1 HAI, and 13 with 2 HAIs
# 9 patients with 1 HAI, and 3 with 2 HAIs
§ 16 patients with 1 HAI
https://doi.org/10.1371/journal.pone.0199616.t003
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Table 4. Microorganisms isolated from HAIs during pre-PCHS and PCHS phases in I1-I2 hospitals.
Pre-PCHS PCHS
Infections 301 135
Exam not available or negative 27 19
Exam available 274 116
Isolated microorganisms Samples (n,%) Samples (n,%) PCHS vs pre-PCHS
S. aureus 21 (6.3%) 16 (11.6%) -23.8%
Staphylococcus spp. 30 (9.0%) 10 (7.2%) -66.6%
Enterococcus spp. 57 (17.2%) 24 (17.5%) -57.8%
Streptococcus spp. 7 (2.1%) 4 (2.9%) -42.8%
C. difficile 9 (2.7%) 3 (2.2%) -66.6%
E. coli 93 (28%) 27 (19.7%) -70.9%
Klebsiella spp. 19 (5.7%) 12 (8.7%) -36.8%
P. mirabilis 15 (4.5%) 6 (4.3%) -60.0%
P. aeruginosa 15 (4.5%) 10 (7.2%) -33.3%
Enterobacter spp. 8 (2.4%) 1 (0.7%) -87.5%
Citrobacter spp. 3 (0.9%) 0 -100%
A. baumannii 8 (2.4%) 5 (3.6%) -37.5%
Morganella spp. 3 (0.9%) 0 -100%
Other Enterobacteriaceae 1 (0.3%) 0 -100%
Candida spp. 26 (7.8%) 11 (8.0%) -57.7%
Virus 5 (1.5%) 3 (2.1%) -40.0%
Others 12 (3.6%) 5 (3.6%) -58.3%
Total 332 (100%) 137 (100%) -
During pre-PCHS phase, 301 HAIs included 13 co-infections; during PCHS phase, 135 HAIs included 6 co-infections.
https://doi.org/10.1371/journal.pone.0199616.t004
Table 5. Risk factors associated with HAI onset in patients of I1-I2 hospitals: Multivariable model
.
Population characteristics P OR 95% CI
Male 0.01812 0.78 0.63–0.96
Age 65–74 vs Age <65 0.0047 1.71 1.18–2.48
Age 75–84 vs Age <65 0.0004 1.88 1.33–2.67
Age 85 or more vs Age <65 0.0026 1.78 1.22–2.58
Length of stay p<0.0001 1.08 1.07–1.09
Incontinence 0.2253 0.85 0.66–1.10
Disorientation 0.0226 1.37 1.05–1.76
Self-sufficiency 0.5600 0.92 0.69–1.43
Pressure sores 0.9757 0.99 0.69–1.44
Ventilation 0.7702 1.07 0.68–1.67
ATB 2 week before 0.8479 0.97 0.68–1.37
MDRO at admission 0.6230 0.86 0.47–1.57
Urinary catheter (any type) p<0.0001 2.68 2.10–3.41
CVC 0.0001 1.99 1.40–2.82
PCHS p<0.0001 0.44 0.35–0.54
 multivariable model included all the factors emerged as significantly associated with HAI onset by univariate
analysis (11,461 patients).
https://doi.org/10.1371/journal.pone.0199616.t005
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statistically significant risk factors the presence of urinary or central venous catheters (re-
spectively OR = 2.68; 95% CI, 2.10–3.41 and OR = 1.99; 95% CI 1.40–2.82), showed PCHS use
as a statistically significant independent protective effect (OR = 0.44; 95% CI, 0.35–0.54)
(P<0.0001).
Impact of sanitation on hospital surface microbiota
Surface bioburden analyses, including detection and quantification of Staphylococcus spp.,
Enterobacteriaceae spp., Pseudomonas spp., Acinetobacter, Clostridium difficile and Candida
spp., showed a persistent contamination in all the enrolled wards in pre-PCHS period, with an
overall pathogen load corresponding to 22,737 CFU/m2 (median value, range 17,053–60,632
CFU/m2), mostly attributable to Staphylococcal contamination (median load 21,895 CFU/m2,
range 13,684–57,263 CFU/m2). Other microbial genera were less abundant: Enterobacteriaceae
(median value 1,784 CFU/m2; range 444–3,015 CFU/m2), Acinetobacter (mean value 2,538
CFU/m2; range 214–3,836 CFU/m2), Pseudomonas spp. (mean value 361 CFU/m2; range 43–
2,125 CFU/m2), C. difficile (mean value 286 CFU/m2; range 137–842 CFU/m2) and Candida
spp. (mean value 1,480 CFU/m2; range 1,075–5,508 CFU/m2) (supporting information files in
BioStudies repository, Accession No. S-BSST75).
The introduction of PCHS in the five intervention hospitals (I1 and I2 groups) induced a
statistically significant decrease of pathogen contamination from 22,737 CFU/m2 to 4,632
CFU/m2 (median value; range 842–12,632 CFU/m2) (P<0.0001, corresponding to a mean 83%
decrease of surface pathogen load (range 70–96.3%) (Fig 3A). By contrast, no variations were
observed in the external control hospital between the two observation periods.
Meanwhile, the quota of PCHS-Bacilli increased significantly on surfaces of intervention-
hospitals from 0% (median value, range 0–30%) to 69.8% (median value, range 39.9–86.8%) of
the total surface microbiota (P<0.0001) (Fig 3B). No increase in Bacillus counts was observed
in the extC control hospital.
Microarray analysis of the microbiota resistome showed a significant global decrease of
resistance genes in the I1-I2 hospitals during the PCHS-phase compared to what detected in
the pre-PCHS period (P<0.0001; Pc = 0.008)(S1 Fig)(supporting information files in BioStu-
dies repository, Accession No. S-BSST75). The prevalence of R genes was different in the indi-
vidual hospitals, likely reflecting the selective pressure exerted in each setting, but the decrease
of the R genes originally present during the pre-PCHS phase was observed in all hospitals. No
decrease was instead observed in the external control hospital.
In parallel, resistome microarray analysis of PCHS-Bacilli isolates from surfaces of treated
hospitals, showed no acquisition of R genes in all tested isolates during the whole study period
(Fig 4), confirming previous studies supporting the genetic stability of the PCHS-Bacillus
strains.
Discussion
The role of persistent surface contamination in HAI transmission is recognized [6, 8–11], but
the impact of environmental cleaning on HAI incidence lacks of robust data, since so far most
studies correlating environmental bioburden with HAIs incidence considered a bundle of fac-
tors, or were limited to specific ward types (i.e. ICU)[32, 33].
Since we recently reported that a probiotic-based sanitation (PCHS) can modulate surface
hospital microbiota [27, 29], the present pre-post interventional study was aimed to investigate
directly the potential impact of this system on HAI incidence.
According to our results, in the absence of any other ICP intervention, PCHS was associ-
ated with a significant reduction (P<0.0001) of HAI incidence in the medical wards of acute
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Fig 3. Surface contamination in the surveyed hospitals. (A) Pathogen load on hospital surfaces, expressed as CFU/m2. Six
pathogens were measured by direct CFU counting on specific Rodac plates, as described in Methods (Staphylococcal spp.,
Enterobacteriaceae spp., Acinetobacter spp., Candida spp., Pseudomonas spp., Clostridium spp.). Graphed results represent
the sum of the median values obtained for each measured pathogen. Median values (lower part of the box) and Q3 values
(upper part of the box, representing the 75% percentile values) are shown for each hospital, and for pre-intervention (pre-
PCHS) and intervention (PCHS) phases. Values reported for the external control hospital (Messina), correspond to those
detected in the 1st and 2nd 6-month periods of the study. (B) Total bacterial load and PCHS-Bacilli count, respectively
measured by a pan-bacterial qPCR (panB) and a specific qPCR for Bacillus genus (spo0A). Results are expressed as genome
copy number per 100 ng of tested DNA. The median values ± SD of pre-PCHS and PCHS phases are shown. Values reported
for the external control hospital (Messina), correspond to those detected in the 1st and 2nd 6-month periods of the study.
https://doi.org/10.1371/journal.pone.0199616.g003
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Fig 4. Resistome analysis of PCHS-Bacillus strains. Antibiotic resistance genes were analyzed by microarray both in
the PCHS detergent prior to application, containing a blend of three Bacillus species (Original) and in the Bacillus
isolates (Isolates) collected from hospital surfaces in the PCHS phase of I1 and I2 hospital groups. For original PCHS-
Bacilli, results are expressed as mean values ± SD of six replicates. For Isolates, results are expressed as the mean
value ± SD of 120 Bacillus isolated from hospital surfaces. Both Original and Isolates values were compared to negative
control values (NTC). Each Bacillus isolate was identified by PCR and sequencing prior to microarray analysis, as
previously described [29].
https://doi.org/10.1371/journal.pone.0199616.g004
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hospitals. The reduction was observed in all HAIs commonly detected in internal medicine
wards, some of which are associated with contact transmission, and this was associated with a
concurrent decrease of the responsible isolated microorganisms, while their relative frequen-
cies remained unaltered.
Multivariable analysis, while confirming the role of well known risk factors [34], such as the
presence of catheters (OR = 2.68 and OR = 1.99 for urinary and CVC, respectively), revealed
PCHS to be an independent protective factor (OR = 0.44; 95% CI, 0.35–0.54) (P<0.0001).
Furthermore, the bioburden data confirmed in a large sample that PCHS is able to reduce
and remodulate the environmental contamination, inducing a significant decrease (-83%) of
the overall surface pathogen load as well as of the resistance genes harboured by the surface
microbiota (up to 2 Logs) [27–29], suggesting that probiotic Bacilli can displace and replace
pre-existing pathogens, limiting colonization and spreading of new potentially pathogenic and
drug-resistant entries (contamination from care-givers, new patients, healthcare workers), a
competitive mechanism well known in nature [35–38].
In addition, microbiological and molecular systematic monitoring of the present study sup-
ports the safety of use of PCHS observed in previous trials [26, 27, 39], confirming the genetic
stability of the PCHS-Bacilli and the absence of any infectious risk correlated to the use of
PCHS probiotics in hospital settings.
Limitations
Although showing a strong protective effect of PCHS, this study has some potential limita-
tions. A first possible one is related to the study design, which is a pre-post intervention run in
the same hospitals. Nevertheless, the size of the sample and the magnitude of the resulting
reduction seem to indicate a clear role of PCHS. Based on these results, further developments
could include studies based on larger samples and different methodologies, such as stepped
wedge trials and/or cluster randomized trials, including cost effectiveness. Also, the numbers
of the external control hospital are small, and the non significant reduction observed might be
due to this limitation. Since the explored settings are limited to internal medicine, geriatrics
and neurology, further studies would benefit from exploring the impact in other healthcare
settings, in order to better understand the generalizability of the obtained results.
Secondly, the sample size was calculated to detect differences in the global sample and not in
the individual hospitals; nevertheless, the results showed a HAI decrease in all hospitals, although
it was not statistically significant in those hospitals with a low HAI incidence at baseline.
Thirdly, a potential bias might be represented by the awareness of the healthcare personnel
about the study itself, but healthcare professionals were aware only of an incidence study to be
conducted during the whole study period (18 months). Furthermore, this point was addressed
by limiting the information exclusively to hospital managers, recruiting external data collectors
and data extractors, and including an external control hospital to monitor the potential impact
related only to the presence of a study. At the same time it should be considered that the period
of the study was very long (all together the span of time was 18 months), thus limiting the
potential attention bias of the healthcare workers teams.
A further potential bias could be related to seasonality and geographical distribution of the
enrolled hospitals. The 6 month follow-up period may not be sufficient to negate the effects of
seasonal variability, and similarly the lack of enrolled sites from all three regions in both I1 and
I2 groups may be a limitation. Further studies could therefore include a longer follow-up
period and/or a more robust enrolment. Nevertheless, the size and the characteristics of the
HAI reduction and the relative effect in term of displacement of microbiota seems to indicate
that these potential confounders, if existing, could have a limited effect.
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Lastly, although there was an agreement not to introduce measures to improve infection
control in the enrolled hospitals, a potential for confounding is represented by the lack of mea-
surement of hand hygiene over the study period.
Conclusions
This is the first study, to our knowledge, which shows an association between HAI incidence
and environmental microbiota in such a large sample. Overall, collected results may contribute
to emphasize the role of environmental microbiota modulation for cleaning in healthcare set-
tings, introducing the possibility of an ecological approach in the area of environmental clean-
ing, which might be included among the effective tools available for infection prevention and
control (IPC). This could support policies aimed at reducing the development of microbial
resistance to disinfectants and antibiotics, leading to an effective reduction of costs related to
HAI management. On another hand, our results might be useful to introduce methodologies
to investigate environmental bioburden and circulation of resistome in healthcare settings, as
its systematic analysis might open the possibility to explore new strategies in controlling its
spread. Last, this study opens new issues to be explored: the applicability and the impact in dif-
ferent settings, the impact on different types of HAIs, the long-term effect of the routine use of
PCHS, the dynamics between human pathogens population and probiotic Bacilli and the
impact on costs related to management of HAIs. Of course, deep analyses about cost effective-
ness will be needed, as well as future studies optimally designed to address information still
lacking in this study.
In conclusion, these results might be important to better understand the role of environ-
mental microbiota in healthcare settings, supporting the development of guidelines about
environmental cleaning addressed to enhance IPC strategies.
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